-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Dementia is an important global health challenge today, so far there is no effective strategy to reverse or cure dementia.
Dementia is an important global health challenge today, so far there is no effective strategy to reverse or cure dementia.
When the systolic blood pressure of middle-aged hypertensive patients exceeds 130mmHg, the risk of cognitive impairment increases significantly.
Studies have shown that the diastolic blood pressure in later life is controlled at the level of 90 to 100mmHg, and the most common dementia-Alzheimer's disease (AD, Alzheimer's disease) has the lowest risk.
The diastolic blood pressure in later life is controlled at the level of 90 to 100mmHg, and the most common dementia-Alzheimer's disease (AD, Alzheimer's disease) has the lowest risk.
JAMA
SPRINT MIND is a multi-center randomized clinical trial that compares the efficacy of two different antihypertensive strategies, conventional antihypertensive and intensive antihypertensive.
diabetes
Participants were randomly assigned to a systolic blood pressure target of <120 mmHg (intensive treatment group: n = 356) or <140 mmHg (standard treatment: n = 317).
The results showed that among the 673 recruited baseline MRI patients (average 67.
There was no significant difference in brain atrophy, cerebral blood flow or even distribution parameters between the two groups of AD patients.
Compared with standard antihypertensive therapy, intensive antihypertensive treatment can delay hippocampal volume reduction.
In summary, strengthening hypertension control cannot reduce the risk of Alzheimer's, but it can delay hippocampal size reduction.
Strengthening the control of high blood pressure does not reduce the risk of Alzheimer’s, but it can delay hippocampal size reduction.
references:
1) Ou YN, et al.
springer.
com/journals/jamaneurology/article-abstract/2776960" target="_blank" rel="noopener">Association of Intensive vs Standard Blood Pressure Control With Magnetic Resonance Imaging Biomarkers of Alzheimer Disease: Secondary Analysis of the SPRINT MIND Randomized Trial.
Leave a message here
